FAM
INSY

Fred Alger Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Fred Alger Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-20,900
Closed -$607K – 558
2015
Q1 		$607K Buy
+20,900
New +$553K ﹤0.01% 535

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fred Alger Management's INSY Position: Q2 2015 in Review

Fred Alger Management sold out of Insys Therapeutics, Inc. (INSY) in Q2 2015, closing a stake of 20,900 shares — an estimated $607K sold.

Fred Alger Management first reported a position in INSY in Q1 2015 and held it in 1 quarter. The position peaked at $607K in Q1 2015. 146 funds tracked by Wall St. Rank hold INSY as of Q2 2015.

  • Fred Alger Management reported no remaining Insys Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Fred Alger Management sold 20,900 Insys Therapeutics, Inc. shares in Q2 2015, an estimated $607K.
  • Fred Alger Management first reported a position in Insys Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Fred Alger Management's Insys Therapeutics, Inc. position peaked at $607K in Q1 2015.
  • 146 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2015.

Based on Fred Alger Management's 13F filing for Q2 2015, filed 14 Aug 2015.